Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 4 (April)

1. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature.
   Int J Dermatol, 47(4): 410-3. [Abstract] [Full-text]
2. Periprocedural anticoagulation for atrial fibrillation ablation.
   J Cardiovasc Electrophysiol, 19(4): 362-6. [Abstract] [Full-text]
3. Effectiveness of pharmacist intervention for asthma control improvement.
   Eur Respir J, 31(4): 790-9. [Abstract] [Full-text]
4. Surgical pleurodesis for Vanderschueren's stage III primary spontaneous pneumothorax.
   Eur Respir J, 31(4): 837-41. [Abstract] [Full-text]
5. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
   J Natl Cancer Inst, 100(7): 475-82. [Abstract] [Full-text]
6. An overview of drug-induced acute kidney injury.
   Crit Care Med, 36(4): S216-23. [Abstract] [Full-text]
7. Oliguria, volume overload, and loop diuretics.
   Crit Care Med, 36(4): S172-8. [Abstract] [Full-text]
8. Fall injuries in older adults from an unusual source: entering and exiting a vehicle.
   J Am Geriatr Soc, 56(4): 609-14. [Abstract] [Full-text]
9. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species.
   Pediatrics, 121(4): 703-10. [Abstract] [Full-text]
10. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis.
    Pediatrics, 121(4): 689-96. [Abstract] [Full-text]
11. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Pediatrics, 121(4): e927-35. [Abstract] [Full-text]
12. Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.
    Pediatrics, 121(4): e787-93. [Abstract] [Full-text]
13. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
    Cancer Res, 68(7): 2312-20. [Abstract] [Full-text]
14. Microfluidic delivery of small molecules into mammalian cells based on hydrodynamic focusing.
    Biotechnol Bioeng, 100(1): 150-8. [Abstract] [Full-text]
15. Bronchopericardial fistula, an unusual complication of oxytetracycline sclerosis therapy.
    Interact Cardiovasc Thorac Surg, 7(2): 280-1. [Abstract] [Full-text]
16. Study of cell killing effect on S180 by ultrasound activating protoporphyrin IX.
    Ultrasonics, 48(2): 135-40. [Abstract] [Full-text]
17. Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
    J Med Virol, 80(5): 772-6. [Abstract] [Full-text]
18. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Cancer Sci, 99(5): 1016-20. [Abstract] [Full-text]
19. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
    Pediatr Blood Cancer, 50(5): 976-82. [Abstract] [Full-text]
20. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
    Pediatr Blood Cancer, 50(5): 970-5. [Abstract] [Full-text]
21. Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
    Pediatr Blood Cancer, 50(5): 1060-2. [Abstract] [Full-text]
22. Bone mineral density deficits in pediatric patients treated for sarcoma.
    Pediatr Blood Cancer, 50(5): 1032-8. [Abstract] [Full-text]
23. Transient ectopic expression as a method to detect genes conferring drug resistance.
    Int J Cancer, 122(11): 2641-5. [Abstract] [Full-text]
24. Dendrimers destabilize proteins in a generation-dependent manner involving electrostatic interactions.
    Biopolymers, 89(6): 522-9. [Abstract] [Full-text]
25. Physiological and medical monitoring for en route care of combat casualties.
    J Trauma, 64(4): S342-53. [Abstract] [Full-text]
26. Closed-loop control of fluid therapy for treatment of hypovolemia.
    J Trauma, 64(4): S333-41. [Abstract] [Full-text]
27. Closed-loop and decision-assist resuscitation of burn patients.
    J Trauma, 64(4): S321-32. [Abstract] [Full-text]
28. Adverse drug reaction-related hospitalisations: a population-based cohort study.
    Pharmacoepidemiol Drug Saf, 17(4): 365-71. [Abstract] [Full-text]
29. Severe labetalol overdose in an 8-month-old infant.
    Paediatr Anaesth, 18(5): 435-8. [Abstract] [Full-text]
30. "Coming to grips" with chemotherapy-induced premature menopause.
    Health Care Women Int, 29(4): 384-99. [Abstract] [Full-text]
31. Is there still a role for double-contrast barium enema examination?
    Clin Gastroenterol Hepatol, 6(4): 389-92. [Abstract] [Full-text]
32. Systemic antibiotic prophylaxis not needed for microsurgical varicocelectomy.
    Urology, 71(4): 669-71. [Abstract] [Full-text]
33. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding.
    Clin Gastroenterol Hepatol, 6(4): 418-25. [Abstract] [Full-text]
34. Colonic washout enemas for persistent constipation in children with recurrent urinary tract infections based on dysfunctional voiding.
    Urology, 71(4): 607-10. [Abstract] [Full-text]
35. Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program.
    Crit Rev Oncol Hematol, 66(2): 163-70. [Abstract] [Full-text]
36. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
    Crit Rev Oncol Hematol, 66(2): 171-80. [Abstract] [Full-text]
37. Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
    Gastroenterology, 134(4): 1224-37. [Abstract] [Full-text]
38. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins.
    Gastroenterology, 134(4): 921-8. [Abstract] [Full-text]
39. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Am J Clin Oncol, 31(2): 188-94. [Abstract] [Full-text]
40. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
    Am J Clin Oncol, 31(2): 157-62. [Abstract] [Full-text]
41. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Am J Clin Oncol, 31(2): 151-6. [Abstract] [Full-text]
42. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Am J Clin Oncol, 31(2): 145-50. [Abstract] [Full-text]
43. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
    Am J Clin Oncol, 31(2): 140-4. [Abstract] [Full-text]
44. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Am J Clin Oncol, 31(2): 117-24. [Abstract] [Full-text]
45. Recent developments in germ cell tumors of the testes.
    Curr Opin Oncol, 20(3): 287-93. [Abstract] [Full-text]
46. Advances in nasopharyngeal carcinoma.
    Curr Opin Oncol, 20(3): 264-9. [Abstract] [Full-text]
47. A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update.
    Curr Opin Oncol, 20(3): 249-55. [Abstract] [Full-text]
48. Treatment of recurrent thyroid cancers--is there a light in the horizon?
    Curr Opin Oncol, 20(3): 245-8. [Abstract] [Full-text]
49. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.
    Pediatr Blood Cancer, 50(6): 1169-75. [Abstract] [Full-text]
50. Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP).
    Pediatr Blood Cancer, 50(6): 1138-42. [Abstract] [Full-text]
51. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    J Clin Oncol, 26(11): 1886-92. [Abstract] [Full-text]
52. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    J Clin Oncol, 26(11): 1879-85. [Abstract] [Full-text]
53. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
    J Clin Oncol, 26(11): 1871-8. [Abstract] [Full-text]
54. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    J Clin Oncol, 26(11): 1843-9. [Abstract] [Full-text]
55. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    J Clin Oncol, 26(11): 1830-5. [Abstract] [Full-text]
56. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
    J Clin Oncol, 26(11): 1817-23. [Abstract] [Full-text]
57. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    J Clin Oncol, 26(11): 1858-64. [Abstract] [Full-text]
58. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
    Blood, 111(8): 4004-13. [Abstract] [Full-text]
59. Cytokines as therapeutic targets: advances and limitations.
    Immunity, 28(4): 440-4. [Abstract] [Full-text]
60. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Expert Rev Anticancer Ther, 8(4): 547-51. [Abstract] [Full-text]
61. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Expert Rev Anticancer Ther, 8(4): 525-33. [Abstract] [Full-text]
62. E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.
    Fertil Steril, 89(4): 1018-20. [Abstract] [Full-text]
63. Surgical outcomes after modified antegrade scrotal sclerotherapy: a prospective analysis of 700 consecutive patients with idiopathic varicocele.
    J Urol, 179(5): 1933-7. [Abstract] [Full-text]
64. Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.
    Int J Radiat Oncol Biol Phys, 71(1): 160-6. [Abstract] [Full-text]
65. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Int J Radiat Oncol Biol Phys, 71(1): 187-91. [Abstract] [Full-text]
66. Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer.
    Int J Radiat Oncol Biol Phys, 71(1): 173-9. [Abstract] [Full-text]
67. Effects of adjuvant chemotherapy on bone marrow mesenchymal stem cells of colorectal cancer patients.
    Cancer Lett, 263(2): 197-203. [Abstract] [Full-text]
68. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.
    J Pediatr, 152(5): 622-8. [Abstract] [Full-text]
69. The P2X7 receptor as a therapeutic target.
    Expert Opin Ther Targets, 12(5): 647-61. [Abstract] [Full-text]
70. Targeting of extracellular proteases required for the progression of pancreatic cancer.
    Expert Opin Ther Targets, 12(5): 605-19. [Abstract] [Full-text]
71. The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update.
    Expert Opin Ther Targets, 12(5): 565-81. [Abstract] [Full-text]
72. Novel therapeutic targets in the treatment of IBD.
    Expert Opin Ther Targets, 12(5): 553-63. [Abstract] [Full-text]
73. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    BJOG, 115(6): 773-9. [Abstract] [Full-text]
74. Influence of age and hormone replacement therapy on the functional properties of the lips.
    Skin Res Technol, 14(2): 220-5. [Abstract] [Full-text]
75. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.
    Nat Rev Microbiol, 6(5): 349-62. [Abstract] [Full-text]
76. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
    Clin Cancer Res, 14(8): 2437-43. [Abstract] [Full-text]
77. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    J Natl Cancer Inst, 100(8): 563-71. [Abstract] [Full-text]
78. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    J Natl Cancer Inst, 100(8): 542-51. [Abstract] [Full-text]
79. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    J Natl Cancer Inst, 100(8): 533-41. [Abstract] [Full-text]
80. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
    J Natl Cancer Inst, 100(8): 552-62. [Abstract] [Full-text]
81. Investigation to predict faecal continence in patients undergoing reversal of a defunctioning stoma (Porridge enema test).
    Colorectal Dis, 10(4): 379-85. [Abstract] [Full-text]
82. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway.
    Mol Pharmacol, 73(5): 1491-501. [Abstract] [Full-text]
83. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    J Clin Oncol, 26(12): 2020-6. [Abstract] [Full-text]
84. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    J Clin Oncol, 26(12): 2013-9. [Abstract] [Full-text]
85. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    J Clin Oncol, 26(12): 2006-12. [Abstract] [Full-text]
86. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    J Clin Oncol, 26(12): 1987-92. [Abstract] [Full-text]
87. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    J Clin Oncol, 26(12): 1980-6. [Abstract] [Full-text]
88. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique.
    Clin Infect Dis, 46(10): 1609-16. [Abstract] [Full-text]
89. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
    J Pharmacol Exp Ther, 325(2): 400-8. [Abstract] [Full-text]
90. Effects of estrogen on intracellular signaling pathways linked to activation of muscarinic acetylcholine receptors and on acetylcholinesterase activity in rat hippocampus.
    Biochem Pharmacol, 75(9): 1827-34. [Abstract] [Full-text]
91. A review of irritable bowel syndrome and an update on therapeutic approaches.
    Expert Opin Pharmacother, 9(7): 1129-43. [Abstract] [Full-text]
92. Recommendations and treatment strategies for the management of acute ischemic stroke.
    Expert Opin Pharmacother, 9(7): 1071-85. [Abstract] [Full-text]
93. Pharmacogenetics: from bench to byte.
    Clin Pharmacol Ther, 83(5): 781-7. [Abstract] [Full-text]
94. Nanoparticles in medicine: therapeutic applications and developments.
    Clin Pharmacol Ther, 83(5): 761-9. [Abstract] [Full-text]
95. Failure to intensify antihypertensive treatment by primary care providers: a cohort study in adults with diabetes mellitus and hypertension.
    J Gen Intern Med, 23(5): 543-50. [Abstract] [Full-text]
96. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
    JAMA, 299(16): 1914-21. [Abstract] [Full-text]
97. Local myotoxicity from sustained release of bupivacaine from microparticles.
    Anesthesiology, 108(5): 921-8. [Abstract] [Full-text]
98. Massive pulmonary embolism with cardiac arrest treated with continuous thrombolysis and concomitant hypothermia.
    Emerg Med J, 25(5): 310-1. [Abstract] [Full-text]
99. Communicating risk to emergency department patients with chest pain.
    Emerg Med J, 25(5): 276-8. [Abstract] [Full-text]
100. Model for medication therapy management in a university clinic.
     Am J Health Syst Pharm, 65(9): 844-56. [Abstract] [Full-text]
101. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing--2007.
     Am J Health Syst Pharm, 65(9): 827-43. [Abstract] [Full-text]
102. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
     Am J Ophthalmol, 145(5): 862-74. [Abstract] [Full-text]
103. The effect of physiologic derangement in patients with stroke treated with thrombolysis.
     J Stroke Cerebrovasc Dis, 17(3): 141-6. [Abstract] [Full-text]
104. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
     J Stroke Cerebrovasc Dis, 17(3): 121-8. [Abstract] [Full-text]
105. Dietary boron and hormone replacement therapy as risk factors for lung cancer in women.
     Am J Epidemiol, 167(9): 1070-80. [Abstract] [Full-text]
106. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.
     Br J Ophthalmol, 92(5): 705-11. [Abstract] [Full-text]
107. Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review.
     Br J Ophthalmol, 92(5): 588-93. [Abstract] [Full-text]
108. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
     Br J Ophthalmol, 92(5): 661-6. [Abstract] [Full-text]
109. Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations.
     Br J Ophthalmol, 92(5): 655-60. [Abstract] [Full-text]
110. Modifications of HIV-1 DNA and provirus-infected cells during 24 months of intermittent highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 48(1): 68-71. [Abstract] [Full-text]
111. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
     Cancer, 112(9): 1983-91. [Abstract] [Full-text]
112. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
     Cancer, 112(9): 2021-9. [Abstract] [Full-text]
113. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
     Prostate, 68(8): 861-71. [Abstract] [Full-text]
114. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
     Prostate, 68(8): 820-9. [Abstract] [Full-text]
115. Photodynamic therapy followed by thoracoscopic sleeve lobectomy for locally advanced lung cancer.
     Ann Thorac Surg, 85(5): e24-6. [Abstract] [Full-text]
116. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
     Cancer Invest, 26(4): 431-3. [Abstract] [Full-text]
117. Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
     Cancer Invest, 26(4): 426-30. [Abstract] [Full-text]
118. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
     Cancer Invest, 26(4): 401-6. [Abstract] [Full-text]
119. Quantification of microspheres appearance in brain vessels: implications for residual flow velocity measurements, dose calculations, and potential drug delivery.
     Stroke, 39(5): 1476-81. [Abstract] [Full-text]
120. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke.
     Stroke, 39(5): 1464-9. [Abstract] [Full-text]
121. Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis.
     Stroke, 39(5): 1613-5. [Abstract] [Full-text]
122. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study.
     Stroke, 39(5): 1487-90. [Abstract] [Full-text]
123. Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study.
     Stroke, 39(5): 1556-62. [Abstract] [Full-text]
124. Clinical and tissue response to intravenous thrombolysis in tandem internal carotid artery/middle cerebral artery occlusion: an MRI study.
     Stroke, 39(5): 1616-8. [Abstract] [Full-text]
125. Staged escalation therapy in acute basilar artery occlusion: intravenous thrombolysis and on-demand consecutive endovascular mechanical thrombectomy: preliminary experience in 16 patients.
     Stroke, 39(5): 1496-500. [Abstract] [Full-text]
126. Intra-arterial thrombolysis of acute iatrogenic intracranial arterial occlusion attributable to neuroendovascular procedures or coronary angiography.
     Stroke, 39(5): 1491-5. [Abstract] [Full-text]
127. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
     J Clin Oncol, 26(13): 2178-85. [Abstract] [Full-text]
128. Potential regional differences for the tolerability profiles of fluoropyrimidines.
     J Clin Oncol, 26(13): 2118-23. [Abstract] [Full-text]
129. Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.
     Oncology, 73(3): 270-2. [Abstract] [Full-text]
130. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
     Oncology, 73(3): 228-37. [Abstract] [Full-text]
131. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.
     Oncology, 73(3): 210-4. [Abstract] [Full-text]
132. Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial.
     Oncology, 73(3): 198-203. [Abstract] [Full-text]
133. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
     Oncology, 73(3): 185-91. [Abstract] [Full-text]
134. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
     J Clin Oncol, 26(13): 2171-7. [Abstract] [Full-text]
135. What happens to patients on antiretroviral therapy who transfer out to another facility?
     PLoS ONE, 3(4): e2065. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.